학술논문
Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial
Document Type
Report
Author
Source
Food Science & Nutrition. October 2023, Vol. 11 Issue 10, p5967, 11 p.
Subject
Language
English
ISSN
2048-7177
Abstract
INTRODUCTION In the twenty‐first century, diabetes is one of the leading causes of debility and death, with an ascending prevalence pattern (Hu, 2011; Wild et al., 2004). Diabetes predisposes patients [...]
: This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation and its safety in T2D patients. This randomized, double‐blinded, placebo‐controlled, parallel‐arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day of vitamin C or a matching placebo for 8 weeks. Of the 70 subjects assigned to the trial, 57 were included in the statistical analysis (vitamin C: n = 32, placebo: n = 25). Inflammatory and oxidative markers, including advanced glycation end products (AGEs), malondialdehyde (MDA), advanced oxidation protein products (AOPP), oxidized low‐density lipoprotein (ox‐LDL), highly sensitive C‐reactive protein (hs‐CRP), tumor necrosis factor‐α (TNF‐α), and ferric reducing ability of plasma (FRAP) were measured at baseline and the end of the trial. In addition, vitamin C tolerance was evaluated. A nutritionist visited all participants for a standard diabetic regimen. Following vitamin C supplementation, the serum levels of MDA (p‐value
: This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation and its safety in T2D patients. This randomized, double‐blinded, placebo‐controlled, parallel‐arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day of vitamin C or a matching placebo for 8 weeks. Of the 70 subjects assigned to the trial, 57 were included in the statistical analysis (vitamin C: n = 32, placebo: n = 25). Inflammatory and oxidative markers, including advanced glycation end products (AGEs), malondialdehyde (MDA), advanced oxidation protein products (AOPP), oxidized low‐density lipoprotein (ox‐LDL), highly sensitive C‐reactive protein (hs‐CRP), tumor necrosis factor‐α (TNF‐α), and ferric reducing ability of plasma (FRAP) were measured at baseline and the end of the trial. In addition, vitamin C tolerance was evaluated. A nutritionist visited all participants for a standard diabetic regimen. Following vitamin C supplementation, the serum levels of MDA (p‐value